Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-101 for Hot Flashes in Menopausal Women
NCT05312567Phase 2Completed
- Sponsor
- Fervent Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vasomotor symptoms comparing Active Treatment (FP-101) with Matching Placebo (2 arms). Primary endpoint: Change in the frequency (average daily number) of moderate-to-severe hot flashes at 1 week. Started Mar 2021; status: completed.
02
Drugs
FP-101
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05312567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312567.